Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000010466
- Lead Sponsor
- Kansai medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
1) Symptomatic brain metastasis 2) Active double cancer 3) Scheduled operation 4) Patients with a history of severe hypersensitivity to drugs used in this trial 5) Uncontrolable hypertension 6) Currently have or have a history of a Ascites ,Pleural effusion or pericardial effusion which requires treatment 7) Problematic infection 8) Uncontrolable complications 9) Sever complications 10) Pregnant or lactation women, or women with known or suspected pregnancy 11) Decision of ineligibility by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate for intracranial metastases
- Secondary Outcome Measures
Name Time Method Safety, Overall Response Rate(ORR), Disease Control Rate(DCR), Progression Free Survival(PFS)